Did someone say J&J will be there tomorrow?17 Sep 2025 12:44
January 2025 -
"Johnson & Johnson (JNJ) entered a merger agreement on January 13, 2025, to acquire drugmaker Intra-Cellular Therapies, Inc. (ITCI) in an all-cash deal valued at $14.6 billion.
Deal Structure:
Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash, representing a premium of 39.14% from the stock’s last close.
Company Profile:
Intra-Cellular is a biopharmaceutical company that develops innovative treatments for psychiatric and neurologic disorders by targeting intracellular signaling mechanisms, including its flagship drug Caplyta for schizophrenia and bipolar depression.
Johnson & Johnson is a global healthcare leader that develops and manufactures innovative products across pharmaceuticals, medical devices, and consumer health, focusing on preventing, treating, and curing complex diseases.
Deal Details and Timeline:
The deal is the latest in a series of acquisitions by Johnson & Johnson to drive growth beyond 2025. Recent acquisitions include Shockwave Medical for $13 billion, and Ambrx Biopharma for $1.33 billion in 2024, Momenta Pharmaceuticals in 2020, and Abiomed in 2022.
With the latest deal, Johnson & Johnson will acquire access to Intra-Cellular’s oral drug Caplyta, which is approved for treating schizophrenia and depressive episodes linked to bipolar disorder.
Intra-Cellular is also pursuing expanded regulatory approval in the U.S. for Caplyta as an adjunct therapy for major depressive disorder. The company is also conducting mid-stage trials of another therapy, ITI-1284, for the treatment of generalized anxiety disorder and Alzheimer’s-related psychosis and agitation.
Johnson & Johnson expects to finance the Intra-Cellular transaction, which is anticipated to close later this year, through a combination of cash on hand and debt. Johnson & Johnson will acquire Intra-Cellular at a multiple of 20.86 times its sales."
source:insidearbitrage.com